---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: NIH phase 1-2a trial"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: NIH phase 1-2a trial. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 68 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence/nih-phase-1-2a-trial"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: NIH phase 1-2a trial

<a id="heading-3.1.6"></a>

## 3.1.6 NIH Phase 1-2a Trial

<a id="heading-3.1.6.1"></a>

### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

#### Trial objectives: safety, tolerability, feasibility, pharmacokinetics, and active dose

> “The objectives of this study are to assess the safety, tolerability, feasibility, and pharmacokinetics (PK) of intrathecally (IT) administered HP-Beta-CD to NPC1 patients, to determine an active dose of HP-Beta-CD as measured by changes in plasma 24-(S) hydroxycholesterol (24(S)-HC) concentration, and to evaluate the use of biomarkers and potential clinical outcomes of NPC1.”

Source: [ClinicalTrials.gov NCT01747135](https://clinicaltrials.gov/study/NCT01747135)

<a id="topic-3.1.6.1-2"></a>

#### Primary objective of safety and primary pharmacodynamic objective of 24(S)-hydroxycholesterol response

> “Safety and tolerability of HPβCD was the primary objective, and 24(S)-hydroxycholesterol (24(S)-HC) response was the primary pharmacodynamic objective.”
> “Here we present the ad-hoc analysis of an 18-month non-randomized, open-label, phase 1/2a trial to determine safety and potential efficacy of escalating doses of lumbar intrathecal HPβCD in NPC1 participants.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.1-3"></a>

#### Objective of the 36-month neuropsychological follow-up analysis

> “The objective of this current analysis was to evaluate the change in neurodevelopmental outcomes at up to 36 months post-baseline in this Phase 1/2a trial of escalating doses of lumbar intrathecal HPβCD in NPC1.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="heading-3.1.6.2"></a>

### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

#### Registry dates, enrollment, and single study location

| Field | Quoted record |
| --- | --- |
| Study start | “2013-01” |
| Primary completion (actual) | “2017-03” |
| Study completion (actual) | “2017-03” |
| Location | “National Institutes of Health Clinical Center, 9000 Rockville Pike” |
| City and state | “Bethesda, Maryland, United States, 20892” |

Source: [ClinicalTrials.gov NCT01747135](https://clinicaltrials.gov/study/NCT01747135)

<a id="topic-3.1.6.2-2"></a>

#### IND submission in December 2012 and trial start in February 2013

> “The IND was submitted in December 2012, and the Phase I Clinical Trial began in February 2013.”

Source: [Ottinger et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4048128/)

<a id="topic-3.1.6.2-3"></a>

#### Enrollment periods at the NIH Clinical Center and Rush University Medical Center

> “NIH participants were enrolled between September 2013 and January 2015. RUMC participants were enrolled between December 2013 and June 2014.”
> “Both the phase 1/2a trial of HPβCD (13-CH-0001) and the NPC1 NHx trial (06-CH-0186) were approved by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Institutional Review Board.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.2-4"></a>

#### Assessments at the NIH Clinical Center in Bethesda

> “During each visit to the NIH Clinical Center in Bethesda, MD, USA, assessments of adverse events and clinical efficacy were performed.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="heading-3.1.6.3"></a>

### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

#### Label description of Trial 2: 78-week, non-randomized, open-label, single-center dose escalation trial

> “Trial 2 (NCT01747135) was a 78-week, non-randomized, open-label, single-center cohort, dose escalation trial that enrolled a total of 14 patients between 4 and 23 years of age”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.6.3-2"></a>

#### Registry design: phase 1, non-randomized, open-label, single-center study with 3-patient dose cohorts

> “In this Phase 1, non-randomized, open-label, single-center, study, we propose to administer HP-Beta-CD intrathecally via lumbar injection to drug naive cohorts of 3 patients at doses of 200 mg escalated to 300, 400 mg and 900 mg.”
> “All patients in the cohort will receive HP-Beta-CD (n = 3) once monthly for at least two doses, and the decision to dose-escalate will be based on safety and on biochemical data.”

Source: [ClinicalTrials.gov NCT01747135](https://clinicaltrials.gov/study/NCT01747135)

<a id="topic-3.1.6.3-3"></a>

#### Open-label dose escalation with a natural history comparison cohort and a parallel every-two-week cohort at RUMC

> “An open-label, dose-escalation study was conducted to evaluate safety, pharmacodynamics, and efficacy of monthly intrathecal doses of 50–1200 mg of a well-characterized HPβCD mixture with a specific compositional fingerprint and limits for impurities (appendix p 3, VTS-270, Vtesse Inc., Gaithersburg MD).”
> “To explore the potential effect of every two week dosing, three additional participants were enrolled in a parallel study at Rush University Medical Center (RUMC, appendix p 2).”
> “Clinical efficacy was ascertained by comparing NSS progression in the 14 NIH HPβCD-treated participants to that observed in a historical cohort of 21 participants of similar age range (table, appendix figure 3, p 12) followed in a NHx study.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.3-4"></a>

#### Choice of the lumbar intrathecal route

> “We elected to use lumbar intrathecal administration since HPβCD does not efficiently cross the blood-brain-barrier”
> “In addition, intrathecal administration avoids potential pulmonary toxicity associated with high-dose systemic delivery”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.3-5"></a>

#### Original plan for intracerebroventricular delivery and adaptive dose escalation design

> “Pre-clinical studies were therefore directed towards supporting ICV administration of HP-β-CD in the Phase I trial using an Ommaya reservoir for delivery, Table (1).”
> “The Phase I trial is an adaptive, dose escalation study designed to systematically determine a safe and biochemically effective dose of HP-β-CD.”

Source: [Ottinger et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4048128/)

<a id="topic-3.1.6.3-6"></a>

#### Study oversight and investigator IND transferred to Vtesse

> “Study monitoring was provided by a study safety committee and an independent Data Safety Monitoring Board. Independent auditing was provided by Amarex Clinical Research (Gaithersburg, MD). An investigator IND supported the study (IND 113273). This IND was subsequently transferred to Vtesse, Inc. (Gaithersburg, MD) to support further drug development.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="topic-3.1.6.3-7"></a>

#### Funding, study drug supply, and role of the funders

> “The funders had no role in study design, data collection, data analysis or decision to submit for publication. Janssen Research & Development, a Johnson and Johnson company provided the study drug and both Janssen Research & Development and Johnson and Johnson provided probono preclinical development support. Vtesse Inc. supported statistical analysis by Statistics Collaborative.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.3-8"></a>

#### NICHD-led design, data collection, and analysis

> “NICHD researchers led the design, data collection and analysis of the phase 1/2a clinical trial.”
> “The drug, 2-hydroxypropyl-beta-cyclodextrin (VTS-270), is being tested under a cooperative research and development agreement, or CRADA, between NIH and Sucampo Pharmaceuticals, Inc.”

Source: [NICHD phase 1-2a trial news release (2017)](https://www.nichd.nih.gov/newsroom/releases/nieman_pick_080917)

<a id="topic-3.1.6.3-9"></a>

#### Use of the trial data for Breakthrough Therapy designation and the phase 2b/3 trial

> “Data from this trial have been accepted by the FDA to support a Breakthrough Drug designation for VTS-270, and have supported the development and implementation of a randomized, sham-controlled, pivotal phase 2b/3 trial approved by both the FDA and EMA.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="heading-3.1.6.4"></a>

### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

#### Inclusion criteria: age, NPC1 diagnosis, neurological manifestation, and stable miglustat dose

> “Aged greater than or equal to 2 and less than or equal to 25 years old at time of enrollment, either gender and any ethnicity.”
> “Patients with at least one neurological manifestation of NPC1. For example, but not limited to, hearing loss, vertical supranuclear gaze palsy, ataxia, dementia, dystonia, seizures, dysarthria, or dysphagia.”
> “Ability to travel to the National Institutes of Health Clinical Center (NIH CC) repeatedly for evaluation and follow-up.”
> “If taking miglustat, the patient must have been taking a constant dose of the medication for no less than 3 months prior to baseline evaluation and must be willing to maintain that dose level for the duration of the trial.”

Source: [ClinicalTrials.gov NCT01747135](https://clinicaltrials.gov/study/NCT01747135)

<a id="topic-3.1.6.4-2"></a>

#### Exclusion criteria: severe or asymptomatic disease, prior cyclodextrin, and conditions affecting lumbar puncture or audiology

> “Severe manifestations of NPC1 that would interfere with the patient's ability to comply with the requirements of this protocol.”
> “Neurologically asymptomatic patients.”
> “Patients who have received any form of cyclodextrin in an attempt to treat NPC1. Treatment with another drug preparation for another medical indication that contains cyclodextrin as an excipient, will not exclude a patient.”
> “Spinal deformity that would impact the ability to perform a lumbar puncture”
> “Contraindication for anesthesia.”
> “Patients unable to complete a behavioral audiologic evaluation including pure-tone threshold assessment (500 Hz to 8000 Hz) to monitor for ototoxicity and for whom otoacoustic emissions (OAEs) cannot be reliably obtained at baseline.”
> “Patients with ongoing seizures, that are not stable in frequency, type or duration over a 2 month period prior to enrollment, requiring change in dose of antiepileptic medication (other than adjustment for weight) over a 2 month period prior to enrollment, or requiring 3 or more antiepileptic medications to control seizures.”

Source: [ClinicalTrials.gov NCT01747135](https://clinicaltrials.gov/study/NCT01747135)

<a id="topic-3.1.6.4-3"></a>

#### Eligible ages and onset category of enrolled participants

> “Eligible participants were aged 2 – 25 years and neurological manifestations, although participants were excluded if these were severe. All participants had neurological symptoms by 13 years of age thus would be categorized as childhood/adolescent onset.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="topic-3.1.6.4-4"></a>

#### Diagnosis by clinical, cellular, and molecular criteria and selection of the comparison cohort

> “The diagnosis of NPC1 disease was established by a combination of clinical, cellular and molecular criteria (appendix pp 2–3).”
> “The NIH NHx population was used as the comparison group, and participants were selected based on two criteria: the presence of two or more assessments within a 25 month time period and an age range of 4 to 24 years at the first of any two or more assessments.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="heading-3.1.6.5"></a>

### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

#### Label description of Trial 2 dosing: 200 to 1,200 mg once monthly

> “LEMBAZ was administered intrathecally at a dosage that ranged from 200 to 1,200 mg once monthly (these dosage regimens are not recommended [see Dosage and Administration (2.2)]), with patients up-titrated based on tolerability and efficacy.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.6.5-2"></a>

#### Formulation, infusion volume, starting doses, and mean doses at 12 and 18 months

> “HPβCD was formulated as a 20% solution and diluted in saline to provide an infusion volume of 10 ml, which was infused over 2–3 minutes.”
> “HPβCD was administered monthly by lumbar intrathecal infusion for the NIH participants. Dosing for CDA101–112 was initiated at 50, 200, 300, or 400 mg HPβCD in groups of 3 participants, and the dose (appendix figure 2, p 11) was advanced based on tolerance and safety data from higher dose cohorts. Mean doses at 12 and 18 months were 289 ± 68 mg and 423 ± 142 for CDA101–112, respectively.”
> “CDA113 and CDA114 were dosed at 900 mg for 12 months. HPβCD was administered every two weeks to the RUMC cohort and their mean dose at 18 months ranged from 297 to 481 mg (figure 1B).”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.5-3"></a>

#### Sequential starting-dose assignment and escalation to 600 or 1200 mg

> “HPβCD (VTS-270) was formulated and provided by Johnson & Johnson (Janssen Research and Development).”
> “Patients were sequentially assigned to starting doses of 50 mg (CDA101–103), 200 mg (CDA104–106), 300 mg (CDA107–109), and 400 mg (CDA110–112). Two participants (CDA113–114) were initially dosed at 900 mg. After initial dosing, participants were dose-escalated (to 600 or 1200 mg) as tolerated.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="topic-3.1.6.5-4"></a>

#### Dose increase for all participants after high doses were tolerated

> “Initially, participants were divided into groups receiving different doses of the drug, but after observing that the drug was safe and well-tolerated by those receiving the highest doses, the researchers increased dosing for all participants.”

Source: [NICHD phase 1-2a trial news release (2017)](https://www.nichd.nih.gov/newsroom/releases/nieman_pick_080917)

<a id="heading-3.1.6.6"></a>

### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

#### 3.1.6.6.1 Rationale for Using Plasma 24(S)-Hydroxycholesterol Area Under the Curve as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

##### Registered primary and secondary outcome measures

| Outcome role | Outcome measure | Time frame |
| --- | --- | --- |
| Primary | “24-hydroxycholesterol Area under the curve” | “Days” |
| Secondary | “Hearing loss.” | “Year” |

Source: [ClinicalTrials.gov NCT01747135](https://clinicaltrials.gov/study/NCT01747135)

<a id="topic-3.1.6.6.1-2"></a>

##### Plasma 24(S)-hydroxycholesterol as a neuron-derived pharmacodynamic marker of cholesterol homeostasis

> “In preclinical studies, treatment with HPβCD was shown to redistribute lysosomal cholesterol, resulting in modulation of a range of central nervous system (CNS) sterol homeostatic responses, including synthesis of 24(S)-HC.”
> “measurement of 24(S)-HC in response to HPβCD provides a pharmacodynamic marker of improved neuronal cholesterol homeostasis.”
> “Plasma 24(S)-HC concentrations were determined at pre-dose, 8, 24, 30, 48, and 72 hours post-dose after either saline or HPβCD infusion and the area under the curve was determined (AUC8–72).”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.6.1-3"></a>

##### Biochemical efficacy defined as change from baseline in plasma 24(S)-hydroxycholesterol

> “Biochemical efficacy will be measured by change from baseline in plasma 24(S)-HC.”

Source: [ClinicalTrials.gov NCT01747135](https://clinicaltrials.gov/study/NCT01747135)

<a id="topic-3.1.6.6.1-4"></a>

##### Secondary efficacy endpoint: NPC Neurological Severity Score

> “Clinical efficacy was evaluated using the NSS.”
> “NPC1 disease progression has been characterized using the NPC Neurological Severity Score (NSS). The NSS is a Likert-like scale that assesses severity of clinically relevant signs and symptoms in nine major and eight minor domains (appendix, p 10).”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.6.1-5"></a>

##### Development of the severity scale and linear progression independent of age of onset

> “The absence of a universally accepted clinical outcome measure is an impediment to the design of a therapeutic trial for NPC. Thus, we developed a clinical severity scale to characterize and quantify disease progression.”
> “Longitudinal chart review of historical data demonstrated that although age of onset varied significantly, the rate of progression appeared linear, independent of age of onset, and similar in all patients.”

Source: [Yanjanin et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2798912/)

<a id="topic-3.1.6.6.1-6"></a>

##### Exploratory CSF biomarkers of neuronal damage: FABP3 and calbindin D

> “CSF levels of fatty acid binding protein 3 (FABP3) and calbindin D were assayed by Myriad Rules Based Medicine (Austin, TX).”
> “Elevated FABP3 has been reported as a biomarker for neurodegenerative disorders”
> “Neither calbindin D nor FABP3 have been established as clinical surrogates, but our observation that CSF levels decrease in temporal relationship with HPβCD therapy is consistent with the conclusion that intrathecal HPβCD decreases neuronal damage in NPC1 participants.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.6.1-7"></a>

##### Neuropsychological outcomes in the 36-month follow-up: IQ and adaptive behavior

> “The primary neurocognitive outcomes in this study were IQ and adaptive behavior.”
> “While conclusions regarding changes over time are limited overall, the presentation of data from various measures and types of scores suggest that the adaptive behavior age equivalent scores are the most clinically useful scores for studies of this nature.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="heading-3.1.6.7"></a>

### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

#### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

##### Actual enrollment of 14 participants

| Field | Quoted record |
| --- | --- |
| Enrollment (actual) | “14” |
| Phase | “Phase 1” |

Source: [ClinicalTrials.gov NCT01747135](https://clinicaltrials.gov/study/NCT01747135)

<a id="topic-3.1.6.7.1-2"></a>

##### Fourteen participants treated monthly and three treated every two weeks, with no formal sample size calculation

> “Intrathecal doses ranging from 50–1200 mg were evaluated in 14 neurologically affected NPC1 participants treated monthly for 12 to 18 months. Three additional participants were treated every two weeks for 18 months.”
> “No formal calculation of sample size was made for ad-hoc analysis of the NSS, and given the small sample size we are not estimating confidence intervals.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.7.1-3"></a>

##### No a priori power calculation for the neuropsychological analyses

> “No a priori power calculation was performed for these analyses.”
> “The sample size in this study is just commensurate with the minimum suggested for valid interpretation of fixed effects and variance (n ≈ 15), but is below that suggested for the standard errors of the fixed effect (n ≈ 30)”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="heading-3.1.6.7.2"></a>

#### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

##### Post hoc mixed model repeated measures analysis of annualized NSS slope versus the natural history cohort

> “A post hoc mixed model repeated measures approach was used to assess the efficacy of HPβCD in this population.”
> “The primary analysis estimates the slope as change in score per year from a mixed model repeated measures (MMRM) model with time, group (HPβCD-treated participants or NIH NHx study participants), and a group by time interaction term.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.7.2-2"></a>

##### Responder analysis based on change from baseline in each NSS domain

> “For the responder analysis, a change from baseline was used to assess the efficacy of HPβCD in individual participants. The NIH NHx population was used as the comparison group; the subject selection criteria were as described for the MMRM approach.”
> “Fisher’s exact test was used for the responder analysis. Unless otherwise specified, data are expressed as mean ± SEM and a nominal p-value of 0.05 was considered significant.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.7.2-3"></a>

##### Audiometric analysis set

> “Behavioral thresholds for pure-tone stimulation could be established for 12/14 participants.”
> “Behavioral audiograms could not be obtained on participants CDA112 and CDA113 due to inability of these participants to perform this testing.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.7.2-4"></a>

##### Neuropsychological analysis set: participants with any available data

> “Participants with any available data were included in analysis; list-wise deletion was not used. However, where missing data resulted in a sample size <10 at more than one major assessment point, parametric analysis was not performed.”
> “No comparison group was available, so the goal of this set of analyses was to describe the course of the neuropsychological outcomes during the trial.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="heading-3.1.6.8"></a>

### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

#### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

##### Timing of the final NSS evaluation by participant

> “NSS evaluations were at 18 months for participants CDA101 and CDA103–111. The 18-month evaluation for CDA112 was obtained at 19 months. NSS data corresponding to CDA102, CDA113 and CDA114 were obtained at 12 months and data corresponding to the three RUMC participants were obtained at 18 months.”
> “Enrollment of participants at the NIH Clinical Center (n=14) between September 2013 and January 2015 and participants at RUMC (n=3) between December 2013 and June 2014.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.1-2"></a>

##### Follow-up to 36 months for neuropsychological outcomes

> “This analysis includes outcomes collected out to 36 months post-baseline.”
> “Fewer than 10 WRAML observations were available at most timepoints (including baseline), so these data were not subjected to parametric analysis.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="heading-3.1.6.8.2"></a>

#### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

##### Baseline characteristics of the NIH treated cohort and the natural history comparison cohort

| Characteristic | Natural History Cohort (n=21) | NIH HPβCD Treated Cohort (n=14) |
| --- | --- | --- |
| Total NSS at baseline, mean | “14.5 ± 9.7” | “19.3 ± 7.5” |
| Total NSS at baseline, median (range) | “14 (1–35)” | “19(5–32)” |
| Total NSS-hearing at baseline, mean | “13.2 ± 9.4” | “17.0 ± 7.4” |
| Age of first neurological symptom, years, mean | “5.4 ± 4.2” | “5.9 ± 3.5” |
| Age of diagnosis, years, mean | “7.1 ± 6.5” | “9.1 ± 5.6” |
| Age of diagnosis, years, median (range) | “7.0 (0.3–21.0)” | “9.0 (2.0–20.0)” |
| Miglustat use, yes, number (%) | “16 (76)” | “12 (86)” |

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.2-2"></a>

##### Comparability of the treated and natural history cohorts at baseline

> “On average NHx patients were younger and had lower NSS at baseline, but these differences were not significant.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.2-3"></a>

##### Baseline hearing loss in all participants

> “Hearing loss (>15 dB HL for at least one frequency) was present at baseline in all participants. Based on these audiograms, seven participants were candidates for hearing aids.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.2-4"></a>

##### Participant information for the 14 NIH participants in the neuropsychological follow-up

| Characteristic | Mean ± standard deviation | Range |
| --- | --- | --- |
| Age at diagnosis (years) | “9.07 ± 5.65” | “2 − 20” |
| Age at baseline (years) | “15.07 ± 5.53” | “4 − 23” |
| Niemann-Pick Type C1 Total Severity Score at Baseline | “19.29 ± 7.46” | “5 − 32” |

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

| Characteristic | n (%) |
| --- | --- |
| Female | “7 (50%)” |
| White | “14 (100%)” |
| Non-Latino/Non-Hispanic | “13 (93%)” |
| Hearing loss at baseline | “11 (79%)” |
| Seizures | “5 (36%)” |
| Miglustat | “11 (79%)” |

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="heading-3.1.6.8.3"></a>

#### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

##### Plasma 24(S)-hydroxycholesterol response after intrathecal dosing

> “The majority (121/155) of post-drug plasma 24(S)-HC AUC8–72 values were greater than post-saline values; however, plasma responses were more variable and less robust compared to what was observed in preclinical testing (appendix figure 4A, pp 13–14).”
> “Despite the variability, the data suggested a trend for increased 24(S)-HC response at higher doses and significant increases in individual subject responses were observed at 900 and 1200 mg (figures 2A and2B).”
> “Each paired set of pre/post values represents an individual dose: for 900 mg, n=18 doses among 8 subjects; for 1200 mg, n=13 doses among 7 subjects.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.3-2"></a>

##### CSF 24(S)-hydroxycholesterol response in three participants

> “The CSF 24(S)-HC concentrations in three participants treated with 600–900 mg of HPβCD were increased over two-fold”
> “In contrast, the increase in CSF 24(S)-HC concentration after HPβCD administration was unambiguous.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.3-3"></a>

##### CSF FABP3 and calbindin D decreased from baseline

> “Significant decreases were observed when comparing baseline and final CSF FABP3 (D) and calbindin D (E) levels.”
> “We also observed that CSF calbindin D and FABP3 levels, biomarkers of neuronal damage, decreased significantly in the majority of HPβCD-treated participants.”
> “These data provide evidence that treatment with HPβCD shifts, towards normal, CSF biomarkers of CNS pathology.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.3-4"></a>

##### Annualized total NSS progression versus the natural history comparison cohort, as printed in the author manuscript

> “The total NSS for the 14 participants treated monthly increased at a slower rate of 122 ± 0 34 points/year compared to 2 92 ± 0 27 points/year (p=0 0002) for the comparison cohort (figure 4A).”
> “These data demonstrate a significant reduction in disease progression in the HPβCD-treated cohort.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.3-5"></a>

##### NSS domains: decreased progression in ambulation, cognition, and speech and increase in hearing

> “Annualized rate of disease progression is decreased for ambulation, cognition, and speech in the intrathecal HPβCD-treated participants in comparison to the NHx group. Only the hearing subdomain demonstrated a notable annualized increase in progression in the HPβCD-treated group. This is consistent with the known ototoxicity of HPβCD.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.3-6"></a>

##### Responder analysis: 7 of 14 treated participants versus 21 of 21 comparison participants progressed

> “Individuals with a decreased or stable NSS minus hearing were considered to be responders.”
> “In the NHx cohort 21/21 (100%) demonstrated disease progression (figure 4C); whereas, 7/14 (50%) of the participants in the HPβCD-treated group demonstrated disease progression (figure 4D). The RUMC participants treated every 2 weeks were all responders.”
> “Furthermore, a responder analysis showed decreased or stabilized NSS in 10/17 HPβCD-treated participants while 21/21 comparison subjects demonstrated disease progression.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.3-7"></a>

##### Individual pre-treatment and on-treatment NSS in eight participants

> “Individual pre/post NSS for eight participants where pretrial data were available are provided in appendix figure 6 (pp 17–18). Stabilization or slowing of NPC1 disease progression can be appreciated in six of eight participants.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.3-8"></a>

##### Sensitivity analyses: miglustat-treated participants and inclusion of the every-two-week RUMC cohort

> “Sensitivity analyses showed similar results when the analysis was restricted to participants treated with miglustat and were suggestive of increased efficacy with every two week dosing.”
> “The limited data available from the RUMC participants suggests that every two week dosing may be more effective than monthly dosing.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.3-9"></a>

##### Intelligence quotient over 36 months

> “The average annualized change in FSIQ was negative: B = −1.28, SE = 0.70, t(34.2) = −1.83, p =0 .076. The slopes in each of the IQ subdomains were weaker: NVIQ, B = −0.65, SE = 0.82, t(35.3) = −0.79, p = 0.43; VIQ, B = −0.80, SE = 1.02, t(34.3) = −0.79, p = 0.44.”
> “Up to 36-months post-baseline, there were no significant declines in the areas of cognition and adaptive behavior.”
> “In conjunction with previous findings, these results provide support for the slowing of disease progress up to 36 months post-initiation of intrathecal VTS-270.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="topic-3.1.6.8.3-10"></a>

##### Memory scores over 36 months

> “The median change in scaled score was slightly negative at most time points for Memory, Recall, and Recognition.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="topic-3.1.6.8.3-11"></a>

##### Plasma and CSF N-palmitoyl-O-phosphocholineserine in trial participants

> “The plasma samples collected from NPC1 study participants in Phase 1/2a trial of IT HPβCD at pre-dosed time point in each visit were used to evaluate the long-term effect of IT HPβCD on PPCS.”
> “PPCS was decreased, increased, and unchanged in 44% (Figure 2B), 17% (Figure 2C), 33% of subjects (Figure 2D), respectively.”
> “In the IT HPβCD trial, the pre-treatment CSF samples supplied with 2% CHAPS that prevented absorption loss of PPCS were collected from only 2 study participants. CSF PPCS did not change after HPβCD treatment in these 2 individuals (Figure 3E).”

Source: [Sidhu et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7145728/)

<a id="heading-3.1.6.8.4"></a>

#### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.6.8.4-1"></a>

##### Caregiver-interview measure of adaptive behavior: Vineland Adaptive Behavior Scales

> “The Vineland is a semi-structured caregiver interview that assesses adaptive functioning in Communication, Daily Living Skills, Socialization, and Motor Skills (standard scores available only for children under the age of 7 years).”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="topic-3.1.6.8.4-2"></a>

##### Vineland standard scores and age equivalents over 36 months

> “On average, the Vineland-II ABC standard score decreased by 1.76 points per year [SE = 0.67, t(59.1) = −2.62, p = 0.011].”
> “However, examination of the average age equivalent scores (in months) for these domains (shown in Figure 2) indicated that the small decreases in standard scores were not due to worsening, but rather to slower-than-typical (or no) acquisition of skills.”
> “Annualized slopes for each of the domain age equivalents were positive, although the 95% CI included zero: Communication [B = 0.71, SE = 3.12, t(60.7) = 0.23, p = 0.82], Socialization [B = 2.99, SE = 2.92, t(60.4) = 1.03, p = 0.30], Daily Living Skills [B = 2.76, SE = 2.76, t(60.3) = 1.18, p = 0.24], and Motor Skills [B = 1.42, SE = 0.94, t(50.5) = 1.51, p = 0.14].”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

<a id="topic-3.1.6.8.4-3"></a>

##### Effect of treatment-related hearing loss on daily communication

> “When managed with hearing aids, this did not have an appreciable impact on daily communication.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.4-4"></a>

##### Hearing aids and daily life

> “In the current study, hearing loss was compensated with hearing aids, which enabled participants to go about their daily lives.”

Source: [NICHD phase 1-2a trial news release (2017)](https://www.nichd.nih.gov/newsroom/releases/nieman_pick_080917)

<a id="heading-3.1.6.8.5"></a>

#### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

##### Safety assessment methods: CTCAE grading and monthly audiology

> “Severity of adverse events was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. Audiological assessments were obtained monthly prior to each infusion.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.5-2"></a>

##### No drug-related serious adverse events; post lumbar puncture headache and ototoxicity as expected adverse events

> “No drug-related serious adverse events were observed. Mid- to high-frequency hearing loss, an expected adverse event, was documented.”
> “Notable expected adverse events included participants with post lumbar puncture headache (64%, 9/14) and ototoxicity (100%, 14/14).”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.5-3"></a>

##### Transient post-dose unsteadiness and fatigue at doses above 600 mg

> “Notable unexpected adverse events included post-administration unsteadiness and fatigue at doses above 600 mg. This was transient and typically occurred 24–72 hours after dosing. The degree of impairment was variable across participants, but classified as significant in 3/9, 6/12 and 9/9 participants at 600, 900 and 1200 mg, respectively. The unsteadiness and fatigue may variably attenuate with repetitive dosing at a given dose level.”
> “From a safety standpoint, doses up to 1200 mg were generally well tolerated. The transient post-dose ataxia/fatigue observed in this study may be a dose-limiting side effect, especially if the dose or frequency of dosing is increased.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.5-4"></a>

##### Hepatocellular carcinoma in one participant

> “One subject presented with hepatocellular carcinoma during the trial.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.5-5"></a>

##### Additional mid- to high-frequency hearing loss in all participants

> “After HPβCD administration, all participants demonstrated additional mid- to high-frequency hearing loss, and all participants were hearing aid candidates.”
> “Broad variation in the degree of ototoxicity in individual participants was observed.”
> “These data suggest that there is greater HPβCD ototoxicity in individuals who have not yet lost hearing due to NPC1 disease itself.”
> “At study end, all participants had functional deficits in hearing, but these deficits did not appreciably impact daily communication when managed with hearing aids.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.8.5-6"></a>

##### Grade 3 hearing loss in one RUMC participant and tinnitus

> “One subject (RUMC03) demonstrated marked sensitivity to HPβCD with CTCAE grade 3 hearing loss upon initial dosing at 400 mg; however, subsequent administration of 300 mg HPβCD every two weeks did not result in additional ototoxicity.”
> “Although not every patient could reliably self-report tinnitus, it appeared to be associated with HPβCD administration. Tinnitus was limited to the post-dose time period in two cases, but persistent in four participants.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="heading-3.1.6.9"></a>

### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

#### Summary: design limitations of the NIH phase 1-2a trial

- Control and external comparison: the trial was a non-randomized, open-label, single-center dose escalation study. The authors state that it “relies on a historical comparison group, and is not a randomized, placebo-controlled trial.” Efficacy compared NSS progression in the 14 NIH participants with a historical cohort of 21 participants from a natural history study, selected for two or more assessments within 25 months and an age of 4 to 24 years. Natural history participants were on average younger and had lower NSS at baseline (mean total NSS 14.5 ± 9.7 versus 19.3 ± 7.5), differences the authors report as not significant.
- Analysis: the clinical efficacy data come from an ad-hoc analysis using a post hoc mixed model repeated measures approach. No formal sample size calculation was made, confidence intervals were not estimated given the small sample size, and the responder analysis used Fisher's exact test with a nominal p-value of 0.05.
- Dose escalation: the authors state that the dose escalation design limits the ability to establish dose-response correlations. The publication describes monthly doses of 50 to 1200 mg in the 14 NIH participants and every-two-week dosing in three additional participants at Rush University Medical Center; the prescribing information describes doses of 200 to 1,200 mg once monthly, regimens it does not recommend.
- Unequal follow-up and measurement: NSS data for three participants (CDA102, CDA113, and CDA114) were obtained at 12 months and for the others at 18 or 19 months. Behavioral audiograms could be obtained for 12 of 14 participants.
- Concomitant miglustat: 12 (86%) treated and 16 (76%) natural history participants used miglustat. In the 36-month neuropsychological analysis, 11 of 14 participants took miglustat at baseline and throughout, and the small number not taking it prevented assessment of its confounding effect.
- Neuropsychological follow-up: the analysis had no comparison or historical control group, was descriptive because the study was not designed to target neuropsychological efficacy, had no a priori power calculation, and had a sample below the n ≈ 30 suggested for the standard errors of the fixed effect. Fewer than 10 WRAML observations were available at most timepoints.
- Confirmation: the authors state that data from a randomized, sham-controlled phase 2b/3 study would be needed to confirm the results.

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/); [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/); [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf); [ClinicalTrials.gov NCT01747135](https://clinicaltrials.gov/study/NCT01747135)

<a id="topic-3.1.6.9-2"></a>

#### Limitations stated by the trial authors: historical comparison group, ad-hoc analysis, and dose escalation design

> “This study has several limitations. First, it relies on a historical comparison group, and is not a randomized, placebo-controlled trial. Second, the clinical efficacy data is based upon an ad-hoc analysis. Third, the dose escalation design focused on determining safety and tolerability limits our ability to establish dose-response correlations with biomarker and clinical data.”
> “Additional work is required to determine if ototoxicity can be separated from neurological efficacy; however, in the context of a lethal neurodegenerative disorder, the risk of functional hearing impairment that can be managed with hearing aids can be justified.”
> “Data from a multicenter, international, randomized, sham-controlled phase 2b/3 study will be needed to confirm the results of this study and obtain FDA and EMA approval.”

Source: [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)

<a id="topic-3.1.6.9-3"></a>

#### Limitations of the 36-month neuropsychological analysis: no control group and concomitant miglustat

> “Additionally, we were not able to include a historical control group.”
> “The descriptive nature of this report was necessary because the study was not designed to specifically target clinical efficacy with respect to neuropsychological functioning. Finally, 11 of 14 participants were taking miglustat at baseline and throughout the trial. Due to the small number of participants not taking miglustat, we were unable to ascertain its potential confounding effect.”

Source: [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)

Additional sources: [Erickson and Fiorenza (2017)](https://pubmed.ncbi.nlm.nih.gov/28803711/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
